(Q37378976)

20 August 2017

1 reference

title

An update on the use of mycophenolate mofetil in lupus nephritis and other primary glomerular diseases (English)

1 reference

20 August 2017

1 reference

Alice S Appel

1

1 reference

PubMed ID

19174771

20 August 2017

Gerald B Appel

series ordinal

2

1 reference

PubMed ID

19174771

20 August 2017

language of work or name

1 reference

27 January 2009

1 reference

Nature Clinical Practice Nephrology

20 August 2017

1 reference

20 August 2017

5

1 reference

20 August 2017

3

1 reference

20 August 2017

132-142

1 reference

Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis.

20 August 2017

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FNCPNEPH1036

Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis

21 January 2018

1 reference

12 December 2020

Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis

1 reference

12 December 2020

Severe lupus nephritis: racial differences in presentation and outcome

1 reference

12 December 2020

Mycophenolate mofetil in anti-MPO renal vasculitis: an alternative therapy in case of cyclophosphamide or azathioprine toxicity

1 reference

12 December 2020

Update on the treatment of lupus nephritis

1 reference

12 December 2020

A randomized control trial of mycophenolate mofeil treatment in severe IgA nephropathy

1 reference

12 December 2020

Efficacy of mycophenolate mofetil on recurrent glomerulonephritis after renal transplantation.

1 reference

12 December 2020

Mycophenolate mofetil and its mechanisms of action

1 reference

12 December 2020

Novel therapy of focal glomerulosclerosis with mycophenolate and angiotensin blockade

1 reference

12 December 2020

Sequential therapies for proliferative lupus nephritis

1 reference

12 December 2020

Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide

1 reference

12 December 2020

The IgA nephropathy treatment dilemma

1 reference

12 December 2020

Frequently relapsing nephrotic syndrome: treatment with mycophenolate mofetil

1 reference

12 December 2020

Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS).

1 reference

12 December 2020

Mycophenolate mofetil impairs transendothelial migration of allogeneic CD4 and CD8 T-cells

1 reference

12 December 2020

Mycophenolate mofetil therapy in lupus nephritis: clinical observations.

1 reference

12 December 2020

Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial.

1 reference

12 December 2020

Mycophenolate mofetil reduces myofibroblast infiltration and collagen III deposition in rat remnant kidney

1 reference

12 December 2020

Mycophenolate mofetil suppresses autoimmunity and mortality in the female NZB x NZW F1 mouse model of systemic lupus erythematosus

1 reference

12 December 2020

Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials

1 reference

12 December 2020

High-dose mycophenolate mofetil in the treatment of posttransplant glomerular disease in the allograft: a case series

1 reference

12 December 2020

Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial

1 reference

12 December 2020

Mycophenolate mofetil inhibits rat and human mesangial cell proliferation by guanosine depletion.

1 reference

12 December 2020

Treatment of idiopathic membranous nephropathy with the combination of steroids, tacrolimus and mycophenolate mofetil: results of a pilot study

1 reference

12 December 2020

Progressive multifocal leukoencephalopathy in transplant recipients

1 reference

12 December 2020

Treatment of lupus nephritis--a work in progress

1 reference

12 December 2020

Minimal change disease in systemic lupus erythematosus

1 reference

12 December 2020

Mycophenolate mofetil for the treatment of interstitial nephritis

1 reference

12 December 2020

Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial

1 reference

12 December 2020

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

1 reference

12 December 2020

Gout in solid organ transplantation: a challenging clinical problem

1 reference

12 December 2020

Mycophenolate mofetil in the treatment of focal segmental glomerulosclerosis.

1 reference

12 December 2020

The classification of glomerulonephritis in systemic lupus erythematosus revisited

1 reference

12 December 2020

Use of mycophenolate mofetil in autoimmune and renal diseases

1 reference

12 December 2020

Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial

1 reference

12 December 2020

Recurrent IgA nephropathy after renal transplantation despite immunosuppressive regimens with mycophenolate mofetil

1 reference

12 December 2020

Use of mycophenolate mofetil in resistant membranous nephropathy.

1 reference

12 December 2020

Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis.

1 reference

12 December 2020

Adult minimal-change disease: clinical characteristics, treatment, and outcomes.

1 reference

12 December 2020

Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil

1 reference

12 December 2020

Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome

1 reference

12 December 2020

Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide.

1 reference

12 December 2020

Progressive multifocal leukoencephalopathy.

1 reference

12 December 2020

Mycophenolate mofetil in idiopathic membranous nephropathy: a clinical trial with comparison to a historic control group treated with cyclophosphamide

1 reference

12 December 2020

A randomized controlled trial of mycophenolate mofetil in patients with IgA nephropathy [ISRCTN62574616]

1 reference

12 December 2020

Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease

1 reference

12 December 2020

Value of a complete or partial remission in severe lupus nephritis

1 reference

12 December 2020

Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group

1 reference

12 December 2020

Outcomes in African Americans and Hispanics with lupus nephritis.

1 reference

12 December 2020

Membranous lupus nephritis in a renal allograft: response to mycophenolate mofetil therapy

1 reference

12 December 2020

Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome

1 reference

12 December 2020

Mycophenolate mofetil in treatment of idiopathic stages III-IV membranous nephropathy

1 reference

12 December 2020

Antiphospholipid antibodies are associated with an increased risk for chronic renal insufficiency in patients with lupus nephritis

1 reference

12 December 2020

Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity

1 reference

12 December 2020

Mycophenolate mofetil treatment for primary glomerular diseases

1 reference

12 December 2020

The safety and efficacy of MMF in lupus nephritis: a pilot study

1 reference

12 December 2020

Effect of mycophenolate mofetil on severity of nephritis and nitric oxide production in lupus-prone MRL/lpr mice

1 reference

12 December 2020

Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide

1 reference

12 December 2020

Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study

1 reference

12 December 2020

Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy

1 reference

12 December 2020

Attenuation of murine lupus nephritis by mycophenolate mofetil.

1 reference

12 December 2020

Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome

1 reference

12 December 2020

"Point of no return (PNR)" in progressive IgA nephropathy: significance of blood pressure and proteinuria management up to PNR.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NCPNEPH1036

1 reference

20 August 2017

1 reference

PubMed ID

19174771